Oncology product candidates are commercialized via LIPAC Oncology, a wholly owned subsidiary of TesoRx Pharma. For more information visit  www.lipaconcology.com .

Oncology product candidates are commercialized via LIPAC Oncology, a wholly owned subsidiary of TesoRx Pharma. For more information visit www.lipaconcology.com.

TesoRx Product Pipeline

TSD-001 is a proliposomal formulation of paclitaxel administered intravesically for the treatment of non-muscle invasive bladder cancer ("NMIBC"). It demonstrated safety and efficacy in preclinical studies and is currently enrolling patients for Phase 1/2a clinical studies. 

TSD-005 is an intravesical treatment with a similar formulation as TSD-001 combined with a proprietary installation device for the treatment of Upper Tract Urothelial Carcinoma ("UTUC"). Phase 2 clinical studies will commence upon the completion of TSD-001's Phase 2a clinical study.

TSX-011 is an oral testosterone for the treatment of men with hypogonadism. It has demonstrated safety and efficacy in extensive pre-clinical studies and is currently completing Phase 1/2a clinical studies. Phase 2 read-out is expected by September 2018 and a Phase 3 clinical study is planned for 2019. TSX-011 has been licensed to ASKA Therapeutics and ASPEN Pharmacare for commercialization in Japan, SE Asia, Latin America, Africa Pacific and Russia CIS.

TSX-002 is an oral testosterone for the treatment of constitutional delay in growth and puberty in boys. It has demonstrated pre-clinical safety and efficacy and established human proof of concept in more than 200 adult male patients. An investigator-led US clinical study is in planning phase to start in 2018.